Still-in-stealth biotech partners with Sloan Kettering scientists to make personalized cancer therapy more 'public' - Endpoints News

One of the obstacles of personalized medicine is that it is, well, personalized. With cancer therapies especially, personalized treatments take money, time, resources and access — all of which are finite. But some scientists instead want to take a more

If the pleasantries exchanged today between the Biogen board and CEO Michel Vounatsos looked a bit intricately scripted to you, even by corporate PR standards, their 10Q filed with the SEC offers a p… [+660 chars]

full article...